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Anxiety involves complex, incompletely understood interactions of
genomic, environmental, and experience-derived factors, and is
currently being measured by psychological criteria. Here, we report
previously nonperceived interrelationships between expression
variations and nucleotide polymorphisms of the chromosome
7q21–22 acetylcholinesterase-paraoxonase 1 (ACHE-PON1) locus
with the trait- and state-anxiety measures of 461 healthy subjects
from the Health, Risk Factors, Exercise Training, and Genetics
Family Study. The AChE protein controls the termination of the
stress-enhanced acetylcholine signaling, whereas the PON protein
displays peroxidase-like activity, thus protecting blood proteins
from oxidative stress damages. Serum AChE and PON enzyme
activities were both found to be affected by demographic param-
eters, and showed inverse, reciprocal associations with anxiety
measures. Moreover, the transient scores of state anxiety and the
susceptibility score of trait anxiety both appeared to be linked to
enzyme activities. This finding supported the notion of correspond-
ing gene expression relationships. Parallel polymorphisms in the
ACHE and PON1 genes displayed apparent associations with both
trait- and state-anxiety scores. Our findings indicate that a signif-
icant source of anxiety feelings involves inherited and acquired
parameters of acetylcholine regulation that can be readily quan-
tified, which can help explaining part of the human variance for
state and trait anxiety.
Anxiety is a ubiquitous and unavoidable experience of life,defined as a feeling of fear that is out of proportion to the
nature of the threat (1). Anxiety disorders are the most prevalent
of psychiatric disorders (2), which led to an extensive search of
the mechanisms andor genomic elements underlying these
phenomena. Several genes were reported to be potential con-
tributors to the genetic variance of anxiety-related traits or
modifiers of the phenotypic expression of pathologic anxiety (3).
However, molecular genetics andor biochemistry have so far
failed to identify variation(s) that are consistently associated
with the increased psychologically measurable susceptibility to
anxiety feelings in generally healthy subjects.
Variance in personality traits is often considered to involve
complex interactions of environmental and experience-derived
factors with several gene products and neurotransmission cir-
cuits [e.g., serotonergic (4), GABAergic, and cholinergic (5)].
Neurotransmission mediated by acetylcholine (ACh) in partic-
ular contributes to numerous physiologic functions (6) as well as
to memory, learning, and panic responses (7, 8). Anxiety pro-
vokes cholinergic hyperarousal (e.g., sweating, intestinal or
gastric constrictions, etc.) (9, 10). In addition, the ACh hydro-
lyzing enzyme acetylcholinesterase (AChE) is a target of pesti-
cides. Human exposure to pesticides, or to the closely related
chemical warfare agents, depletes both AChE and the homol-
ogous enzyme butyrylcholinesterase (BChE) (11), inducing cho-
linergic excitation. Polymorphisms in the corresponding ACHE
and BCHE genes could hence affect both the environmental and
the experience-related elements of anxiety. A third relevant
enzyme is the PON protein product of the paraoxonase PON1
gene, which destroys environmental toxins that target AChE
(12). PON also possesses peroxidase-like activity (13), and can
directly reduce oxidative stress in macrophages and in serum
(14). Polymorphisms in the ACHE, BCHE, and PON1 genes
could therefore affect both the environmental and the experi-
ence-related elements of anxiety.
In mice, we observed that acute stress of even moderate
intensity (e.g., confined swim) causes modulation of the genetic
regulation of ACh availability in the CNS (15). This condition
may be viewed as a laboratory-induced passive gene–
environment interaction, demonstrating that environmental
components of variance for anxiety measures are experience
related, and vice versa. This gene–environment interaction in-
volves overproduction of the readthrough monomeric AChE
(AChE-R) splice variant. Such overproduction acts in the short
term to reduce excess ACh after stress, but at a longer term, is
associated with glucocorticoid-regulated neuronal hyperarousal
and extreme sensitivity to anti-AChEs (16). Transgenic overex-
pression of AChE-R in mice intensifies conflict behavior (17),
another phenomenon associated with anxiety (18). In view of
these findings, we initiated a study aimed at testing whether
genomic polymorphisms in the ACHE-PON1 locus and corre-
sponding changes in serum AChE, BChE, and PON activities
could serve as predictors of the anxiety scores of healthy
humans, assisting the study of this complex phenotype.
Materials and Methods
Study Sample Description. The Health, Risk Factors, Exercise
Training, and Genetics (HERITAGE) Family Study was de-
signed to investigate the role of diverse risk factors in the
genotype on responses to regular exercise (19). Measures of state
and trait anxiety were obtained on a subset of the families as part
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of the study questionnaire. A total of 461 individuals (198 men
and 263 women) from 150 two-generation families of African-
American (172) or Caucasian origin (289) with complete data
were available for this study.
Serum Analyses. Blood samples were collected at baseline in the
morning after a 12-h fast. Questionnaires were completed later
that morning. Serum was prepared by blood centrifugation at
2,000  g (15 min at 4°C). Aliquots of 2 ml in cryogenic tubes
were frozen at 80°C until use. Nondenaturing gel and catalytic
activity measurements of AChE were as described (15). For
other enzyme tests, see Supporting Materials and Methods, which
is published as supporting information on the PNAS web site.
Genotyping. Genomic DNA was prepared from permanent lym-
phoblastoid cells as described (20). PCR amplification by using
Taq polymerase (Sigma, D-6677) was followed by Exo-Sap
enzymatic purification (United States Biochemical, US78200) of
the PCR product (Table 1, which is published as supporting
information on the PNAS web site). Standard automated se-
quencing was performed by using the Big Dye Terminator cycle
sequencing chemistry, ABI 3700 DNA analyzer, and data col-
lection and sequence analysis software (Applied Biosystems).
The 55LM and 192QR coding sequence polymorphisms in
PON1 were detected by using single-nucleotide primer extension
and the SNaPshot method (SNaPshot ddNTP primer extension
kit, ABI), using as probes 5-GGCAGAAACTGG CTCTGAA-
GAC-3 for 55LM and 5-GATCACTATTTTCTTGAC-
CCCTACTTAC-3for 192QR. After extension and calf intes-
tine phosphatase treatment (Amersham Pharmacia Biosciences,
Freiburg, Germany, E2250Y), products were electrophoresed on
a 3700 ABI analyzer and results were analyzed with GENESCAN
software.
Statistics. To test whether observed genotype frequencies con-
formed with the Hardy–Weinberg equilibrium expectations, and
to evaluate the significance of the linkage disequilibrium (LD)
between each polymorphism pair, we used the 2 test.
P values for the difference between the genotypes of the
subjects in distinct trait anxiety subgroups were calculated by
using the likelihood ratio test. The P value was the exact
conditional tail probability given the marginal, as was assessed by
100,000 Monte Carlo simulations. P values for the differences
between AChE, BChE, and PON activities were calculated by
using the two-tailed Student’s t test.
To measure the LD between single-nucleotide polymor-
phisms, we estimated the haplotype frequencies through the use
of the expectation maximization algorithm and calculated Le-
wontin’s D and R2 association values by using the Pearson’s
correlation (21, 22).
Multiple regression analysis was performed by using R statis-
tical software (23). Classification trees were grown by using the
R tree library (24). The tree function in the R software was used
to define a sequence of binary partitions of the population into
subsets based on age, gender, and the different enzyme activities.
Classification trees were ‘‘grown’’ such that, at each step, the
resulting subsets were the most homogeneous, with respect to the
membership in the top 20% state-anxiety group. The tree was
then ‘‘pruned’’ to a number of subsets, or ‘‘nodes,’’ which is
determined by minimizing the misclassification error by a 20-fold
crossvalidation. The process is automatic after selection of the
relevant variables for the analysis.
Results
The psychological phenomenon of anxiety that is experienced by
individuals at a certain time (state anxiety) differs from their
general susceptibility to anxiety (trait anxiety). Both parameters
are commonly measured by the self-reported questionnaires of
the state-trait-anxiety inventory (STAI) (25). To investigate the
role of cholinergic regulation in these measures we used sera,
DNA, and STAI scores from 461 healthy individuals from the
HERITAGE Family Study (19).
Mean STAI scores for the HERITAGE cohort were 35  12
(range 20–80) for trait anxiety and 35 9 (range 16–73) for state
anxiety. Others reported similar values, albeit for far smaller
groups with disease-associated anxiety symptoms (26, 27).
Serum Enzyme Analyses as Surrogate Measures. Our research
spanned three enzymes and genes contributing to balanced ACh
regulation: the closely homologous ACh-hydrolyzing enzymes,
AChE and BChE (and the corresponding ACHE and BCHE
genes), and the organophosphate-hydrolyzing enzyme PON (and
PON1 gene). Significantly higher activities of AChE and BChE
(t test, P 0.006 and P 0.0002, respectively), but not PON (P
0.2), were found in females, as compared with males. Serum
AChE activity was significantly higher in individuals of Cauca-
sian origin (P  0.002); PON activity was significantly higher in
African Americans (P  3  1010), and BChE activity showed
no differences between these populations (P  0.5). AChE and
BChE levels increased with age and body mass index (BMI),
whereas PON activity declined with age.
Trait-, but not state-anxiety scores decreased with age, sug-
gesting that one’s experience andor age provide better protec-
tion from trait, but not state anxiety (Fig. 1 and data not shown).
Also, state- and trait-anxiety measures showed direct, albeit
weak association, both in Caucasians and in African Americans
(Fig. 5, which is published as supporting information on the
Fig. 1. Acquired changes in measured values. Graphs show mean SEM for
each value (n434). Note that trait-anxiety scores decrease with age, whereas
AChE and BChE activities are elevated with both age and BMI.








PNAS web site, and Supporting Materials and Methods). Com-
patible with these changes, an inverse correlation was found
between AChE, but not BChE or PON activities, and trait
anxiety, but not state anxiety (R2  0.93, Fig. 2A), suggesting a
trait-anxiety-predictive role for serum AChE activities. Cortisol
levels, however, did not correlate with trait-anxiety scores, in
agreement with the apparent equivocal relationship between
emotional distress and cortisol (28). Intriguingly, PON but not
BChE or AChE activity, displayed an inverse association with
state anxiety (R2  0.89), suggesting a state-anxiety-predictive
role for this enzyme.
Alternative splicing of ACHE gene products yields at least
three distinct proteins with AChE hydrolytic activity. Of these,
the primary synaptic AChE variant forms tetramers, the eryth-
rocytic AChE-E protein appears as glycophosphoinositide-
bound dimers, and the stress-induced AChE-R variant remains
monomeric (29). Nondenaturing gel electrophoresis followed by
activity staining revealed, in all serum samples, active tetramers
with very small amounts of dimers; however, active monomers
were overrepresented in serum samples from subjects with the
lowest trait-anxiety scores, as compared with those with the
highest scores (Fig. 2B). Immunolabeling of serum protein blots
suggested that serum AChE monomers represent AChE-R (data
not shown and ref. 30), supporting the notion that individuals’
capacity to respond to external stimuli by overproducing mono-
meric AChE-R associates with reduced trait-anxiety scores.
Biochemical Prediction of State-Anxiety Scores. Next, we addressed
the difference between trait and state anxiety. In subjects with
increased serum AChE activity and elevated serum AChE
monomers, the ACHE gene should be close to its maximal
expression capacity. This predicted limited ability for this gene
to react to a changing environment by further overproducing
AChE to suppress the induced stress (15). Therefore, we ex-
pected to find elevated risk for state anxiety in individuals with
higher than expected serum AChE activities. The inverse asso-
ciation of PON levels with state-anxiety measures further sug-
gested an opposite relationship for PON; namely, that individ-
uals with higher then expected serum PON activities would
display reduced risk for state anxiety. To test this working
hypothesis, we calculated the difference between one’s measured
state anxiety and the expected average state anxiety, based on
the demographic parameters. The differences between the mea-
sured and the predicted anxiety values were plotted as a function
of the parallel differences between the measured and predicted
serum AChE and PON activities. This result yielded a significant
two-dimensional interaction between PON and AChE (at P 
0.004, ANOVA, Fig. 2C). These findings implied that subjects
with exceptionally low PON activities may be at greater risk to
develop state anxiety under conditions that fail to trigger AChE
overproduction. This risk would be larger, for example, in aged
subjects due to their considerably lower PON activities and the
corresponding increases in AChE activities, which may explain
the sustained state-anxiety measures in aged subjects. In con-
clusion, serum AChE activities and the reciprocal interaction
with PON activities displayed distinct predictive associations
with STAI scores.
The measured effects were largely independent of family links.
Of the whole data set, 92 informative families with at least two
siblings in each family were further analyzed. Differences be-
tween the serum and anxiety variables of two randomly chosen
siblings from each family revealed low correlations within fam-
ilies both for anxiety and for serum variables, indicating a major
contribution of environmental and experience-derived factors.
The ACHE-PON1 Locus as a Candidate Site. To evaluate the genomic
contribution toward the observed biochemical differences, we
analyzed single-nucleotide polymorphisms in the ACHE, BCHE,
and PON1 genes. The extended human ACHE promoter includes
a functional glucocorticoid response element (GRE), suggesting
overexpression under stress. Israeli subjects frequently carry at
this region an activating deletion associated with constitutively
elevated blood AChE activity and acute anti-AChE hypersen-
sitivity (31). Because this deletion is exceedingly infrequent in
Fig. 2. Serum AChE activity is correlated with trait and state anxiety. (A)
Trait-anxiety associations. Serum AChE activity, but not cortisol levels or BChE
or PON activities, is inversely correlated with trait anxiety. Graphs show
best-fit lines through mean  SEM values of each parameter. (B) Overrepre-
sented AChE monomers in the serum of subjects with low trait-anxiety scores.
Nondenaturing gel electrophoresis of serum samples from subjects with the
noted trait-anxiety scores was followed by enzyme activity staining. Recom-
binant AChE-R and synaptic AChE were similarly separated (but signals were
developed for a shorter time). Note that AChE-R remains monomeric (M),
whereas synaptic AChE includes a significant tetrameric (T) fraction, with
minor dimers (D). (Inset) Shown is quantification of the rapidly migrating
enzyme in the top and bottom 5% trait-anxiety groups. (C) Inverse association
of AChE and PON variations with state anxiety. The differences between the
observed and expected state-anxiety score values of each subject were plotted
as a function of the corresponding differences in serum PON and AChE
activities. Note the increasing tendency for anxious feelings (red) in those
subjects with higher then expected serum AChE activities and the ameliorat-
ing effect on these values of higher than expected PON levels. Smoothness
parameter  0.3.
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the U.S. population (0.34% vs. 3.64% allele frequency in Israe-
lis), we focused as a linkage marker on ACHE’s biochemically
ineffective P446 polymorphism, with 12% frequency in the
HERITAGE subjects, which is compatible with findings of
others (32).
In the PON1 coding region, we genotyped the substitutions
(indicated by amino acid number and symbol) of L55M (TTG
into ATG), reducing PON protein and mRNA levels and Q192R
(CAA into CGA), which affects PONs catalytic efficiency (33).
We also genotyped three known PON1 promoter polymorphisms
(indicated by distance in nucleotides from the translation start
site at 0): 108CT, 162AG, 126GC, contributing to
22.4%, 2.4%, and none of the variation in PON1 expression,
respectively (33). Of the numerous BCHE mutations, we geno-
typed the D70G substitution yielding the ‘‘atypical’’ BChE
variant, with enzymatic activity 30% lower than the wild-type
enzyme (34). Homozygous carriers of this polymorphism display
extreme anxiety after exposure to anti-AChEs (35). Genotypes
at all seven positions did not deviate from Hardy–Weinberg
equilibrium expectations. The PON1 and ACHE genes both map
to the long arm of chromosome 7, with 5.5 Mb separating
between them, whereas the BCHE gene is located on the long
arm of chromosome 3 (Fig. 3A). Therefore, interactions between
PON1 and ACHE, but not BCHE polymorphisms, could reflect
cis effects.
Population and Family Considerations. Because of the presumed
multigenic origin of anxiety phenotypes (1, 2), and the modest
differences between the anxiety symptoms in healthy individuals,
we did not expect drastic genotype-phenotype associations.
Nevertheless, significantly different genotype frequencies were
found in part of the analyzed sites between subjects with a trait-
but not state-anxiety scores in the highest and lowest decile.
Members of the high trait-anxiety group included significantly
more subjects heterozygous for the P446 polymorphism in
ACHE (15 vs. 4 subjects, P  0.03) and significantly more
subjects homozygous to the Alzheimer’s disease- predictive
PON192 variant (13 vs. 5 subjects, P  0.05; ref. 36), whereas
lower trait- anxiety group members included significantly more
subjects heterozygous for the PON-108 polymorphism (23 vs. 11
subjects, P  0.03), and for the PON-126 polymorphism (six vs.
one subject, P  0.05, 2 test).
Next, we jointly considered polymorphism pairs in subjects
from the entire analyzed population, divided evenly into high or
low trait-anxiety scores. Significant contributions to the trait-
anxiety score emerged within the PON1 gene for PON55 with
PON192 (P  0.05) and for PON-126 with PON-162 (P  0.03;
Fig. 3B). Both the average trait anxiety and the allele frequencies
differed significantly between populations (African Americans,
36.1  9.5; Caucasians, 33.7  8.4; t test, P  0.006 for trait
anxiety and P  1.3  105, 2.5  108, 0.02, 0.01, 1.1  106
for ACHE P446, PON108, PON162, PON55, and PON192
respectively, 2 test). Therefore, we considered the possibility of
false positives due to population stratification combined with
trait and allele differences. Significant differences in the PON1
gene between the top and bottom trait-anxiety deciles were,
however, maintained in African-American subjects, despite the
considerably smaller group size, supporting the relevance of this
analysis. Thus, polymorphisms in the ACHE-PON1 locus ap-
peared to be significant, albeit ethnic origin-dependent predic-
tors of trait anxiety, either due to the modified phenotype they
caused or because of LD to other polymorphisms.
Linkages Between the Biochemical and Genetic Data. LD score
analysis of the tested polymorphisms reflected similar patterns
to those described in previous studies (37). In addition to the
predictably high scores within PON1, we found a relatively high
and significant score between the ACHE and PON1 genes (Fig.
4). However, the corresponding r2 correlation coefficients (Fig.
4B) were high within the PON1 gene but low between ACHE and
PON1 polymorphisms, suggesting that the high LD scores were
mainly due to the large differences in the incidence of the studied
polymorphisms.
To better evaluate the implications of the above correlations,
we tested the value of combined individual biochemicalgenetic
polymorphism data for prediction of individuals at risk for
significantly distinct anxiety measures. Regression analysis nor-
malized for gender, age, ethnic origin, and BMI showed a clear
effect of the genotyped markers on the serum activity level of
PON (P  2.2  1016). A smaller, but significant effect was
observed on BChE activity (P  0.04). The effect of the PON1
genotype was also significant when normalized for family rela-
tions (based on the differences between the measurements of
different family members).
We next wished to test whether the genotyped polymorphisms
andor the examined serum enzyme activities affect trait-anxiety
scores. To this end, we applied a general linear model (38), again
after normalizing for the demographic effects, to compare the
most anxious individuals (with the top 20% state-anxiety scores)
against the remaining population. Significant effects emerged
for both the genotyped polymorphisms (P  0.06) and cumula-
tive serum enzyme activities (P  0.005) on the trait-anxiety
score. The population subset with the top 20% trait-anxiety
scores was then classified by using the regression tree method
(24), testing the probability of specific individuals to belong to
the top 20% state-anxiety score group (Fig. 4C). Thus, for
Fig. 3. The analyzed genotypes and their frequencies. (A). Shown are the
chromosome positions and the polymorphic sites that were studied in the
PON1 (GenBank accession no. AF539592), ACHE (GenBank accession no.
AF002993), and BCHE (GenBank accession no. NM000055) genes. Nucleotide
numbers begin at the translation start sites at 0. (B) Distributions and joint
contributions of tested polymorphism pairs with significant effects on trait-
anxiety scores.








example an African-American female younger than 33.4 years of
age with serum AChE activity 237.6 but 194.2 nmol of
hydrolyzed substrate per minml would have a 0% chance of
belonging to the 20% top state-anxiety group (Fig. 4C, note the
numbers at the end of the tree branches). Similar regressions
could be translated into straightforward equations predicting
serum enzyme activities and anxiety scores (Tables 1–5, which
are published as supporting information on the PNAS web site,
and Supporting Materials and Methods).
Discussion
Our findings identified previously nonperceived interactions
between anxiety, serum AChE, BChE, and PON activities, and
their corresponding genotypes. STAI scores were affected by
demographic parameters, and also were significantly associated
with inherited genotype properties combined with the corre-
sponding enzyme activities. The state anxiety capacity to re-
spond to changing conditions was best reflected by higher than
expected serum AChE levels. These scores are less likely to
appear in subjects with high basal activity of serum AChE (e.g.,
aged or overweight individuals), which is compatible with the
prediction of a maximal expression level for this gene that does
not depend on demographic parameters. We have further found
a reciprocal association of the differences between the observed
and predicted AChE and PON activity values, which implies that
PON activity may determine the requirement for AChE over-
production. These interrelationships predict STAI scores dis-
tinctly and significantly, which may open these psychological
parameters for genetic and biochemical tests.
Our laboratory findings correlated significantly with the psy-
chologically examined anxiety scores of the HERITAGE Family
Study subjects. Furthermore, these correlations were common
for individuals of diverse ethnic origins. This finding supports the
notion that these biochemical and genetic factors are causally
related to anxiety: either they reflect inherited elements which
cause or mediate anxiety, or, when enzyme activities are in-
volved, anxiety causes them. Our biochemical findings, based on
self-reported anxiety measures, should be confirmed by a diag-
nostic interview and replicated in an independent sample. More
importantly, replication in a clinically documented anxious
population, compared with a normal population, would contrib-
ute significantly to the clinical value and implications of this
study.
In the HERITAGE cohort, we also found anxiety to be
affected by polymorphisms in the PON1 and BCHE genes, both
having an AChE-protective function. The state-anxiety-
predictive value of the difference between observed and ex-
pected AChE activity is further compatible with our recent
findings that the suppression of the stress-induced AChE-R
variant obliterates conflict behavior (17) and the consolidation
of fearful memories (39). In mammals, responses to anxiogenics
can be modulated by cholinergic agents (40, 41), and subacute
intoxication with organophosphate insecticides induces anxio-
genic effects (42). Altogether, this finding strengthens the
significance of our observations, emphasizes the role of AChE in
environmental challenges, and adds cholinergic regulation and
the ACHE-PON1 locus to the findings of others of genetic
components of anxiety (3). The implications of the cholinergic
system as an important area of investigation may thus extend to
human anxiety disorders, in addition to state and trait measures.
A measured trait of anxiety increases substantially when tested
after stress (43). This change in heritability estimates is generally
thought of as an example of passive gene–environment inter-
action, and the consequence of differential expression of several
polymorphic genes before and after stress. Our current findings
support the notion that the ACHE, BCHE, and PON1 polymor-
phisms can be thought of as part of this polygenic background,
and act as revealers of between, individual differences after
stress or along one’s lifetime. Because both AChE and PON are
targets of organophosphates (PON hydrolyzes them and AChE
is inhibited by them) (44), subjects with high PON activity may
less frequently need to overproduce AChE (e.g., under exposure
to anticholinesterases in fresh crops) (45) than those with low
PON levels. Also, PON hydrolyzes peroxides, thus lowering the
oxidative stress load and protecting other proteins (13), and
AChE is particularly sensitive to oxidative stress (46).
At the expression level, the observed contribution of AChE
regulation to the anxiety scores of otherwise healthy subjects
may be relevant to the recently reported role of ACh in limiting
the production of proinflammatory cytokines (47). Increased
serum AChE, and consequently decreased ACh, would hence
elevate the release of proinflammatory cytokines by macro-
phages. Therefore, serum AChE levels may potentially serve as
predictor of one’s risk of inflammatory responses. Anxiety-
associated roles of such cytokines (48) likely contribute to their
Fig. 4. Combined genotype-phenotype predictions of trait and state anxi-
ety. Shown is the LD analysis of the tested polymorphisms in the healthy
population, presented as absolute D (A) and R2 correlation coefficient values
(B) in parallel matrices. ns, nonsignificant LD. (C) A prediction tree of state-
anxiety values within the population subset with top 20% trait-anxiety scores
based on genotype, age, gender, AChE, BChE, and PON activities. The numbers
at the terminal nodes represent the number of subjects, and below, the
probability of their belonging to the top 20% state-anxiety score group.
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reported effects in autoimmune and atherosclerosis diseases.
This finding, in turn, is compatible with the higher risk for
inflammatory diseases with increasing age and BMI (49, 50).
Anxiety scores, in generally healthy subjects, may hence be
relevant both for psychological and physiological symptoms.
Evaluation of anxiety by genomic and biochemical measures
reflecting the cholinergic balance in the circulation provides a
previously unforeseen approach for studying and perhaps con-
trolling human anxiety.
At the applied level, anxiety disorders aff lict approximately
one of four individuals in the U.S. at some point in their lives,
imposing both an individual and a social burden reaching a total
cost of $42.3 billion in the U.S. in 1990 (2). A large part of these
costs may reflect inappropriate or inefficient treatment of
undiagnosed and misdiagnosed sufferers, highlighting the value
of extensive recognition and effective diagnosis and treatment.
The importance of finding valid measures and diagnostic tools to
properly diagnose and treat anxiety patients lies in the hope to
relieve this individual and social burden. In an era when phar-
macogenomics became a reality (51), and gene-targeted thera-
pies develop rapidly (52), anxiety disorders present a reachable
challenge.
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